BiOptic Inc.

NT$27.50As of Sun 8 Nov 2026, 12:00 UTC

TPEx:6850Healthcare

Country Taiwan

PE (Fwd) 34.41

TSR 5Y CAGR (2.25%)

Div yield —

ROE —

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM (36.54%)

Mkt cap NT$909.9M

ROIC —

SE Grade™

Value

—

Quality

Moat

1Y Price

Reference

NT$29

—

5.36%

—

TTM

FYE 31 Dec TWD

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

—

RevenueNT$M

—

179.3

231.4

228.3

202.7

—

225.0

4.17%

—

Revenue growth%

—

29.07

(1.35)

(11.21)

—

11.01

(1.35)

—

Gross margin%

—

61.57

65.97

66.91

61.81

—

62.22

63.89

—

Operating margin%

—

24.79

28.09

19.46

9.46

—

9.77

22.12

—

Net margin%

—

25.80

26.48

16.54

11.21

—

11.28

21.17

—

P/E ratio (avg)x

—

21.38

35.37

63.91

—

35.90

35.37

—

EV/EBITx

—

17.18

30.34

75.15

—

38.20

30.34

—

FCF yield (avg)%

—

4.78

(9.50)

1.67

—

3.26

1.67

—

FCF margin%

—

13.80

27.05

(55.58)

11.97

—

13.21

12.89

—

FCF / Net incomex

—

0.535

1.022

(3.361)

1.068

—

1.172

0.778

—

ROIC%

—

19.85

28.92

13.26

4.35

—

5.12

16.55

—

Return on equity%

—

12.57

15.58

8.88

5.16

—

5.07

10.72

—

Return on assets%

—

11.03

11.75

6.15

3.81

—

3.92

8.59

—

EPSNT$

—

1.84

1.14

0.69

—

0.77

(38.89%)

—

EPS growth%

—

(38.07)

(39.70)

—

(38.89)

—

Bookvalue per shNT$

—

12.53

13.00

13.56

—

15.11

4.01%

—

FCF per shareNT$

—

1.87

(3.82)

0.73

—

0.90

(37.53%)

—

Dividend per shNT$

—

Div yield (avg)%

—

Payout ratio%

—

33.09

Shares (diluted)M

—

33.39

33.21

33.16

33.12

◌33.12

(0.27%)

—

0.13

Buyback yield%

—

0.53

0.15

0.13

◌—

0.15

—

D/E ratiox

—

0.016

0.034

0.216

0.192

—

0.172

0.113

—

0.910

Enterprise valueNT$B

—

1.117

1.348

1.440

1.448

0.839

9.04%

—

LT debtNT$M

—

76.93

75.00

—

75.00

(2.51%)

—

Peers (US$28.28M)

Cap (US$)

Level Biotechnology…

29.70M

15.30x

TCI GENE Inc.

27.69M

18.25x

Holy Stone Healthcare…

27.03M

—

Nicox S.A.

28.20M

4.176x

Capital

TTM

10Y

Leveragex

—

(1.445)

EBIT/Intx

—

53.02

Own earn%

—

Sh yield%

0.13

0.15

Owners

Insiders/Inst%

23.98

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

4/4

Revenue growth years

1/3

EPS growth years

—

Dividend streakyrs

Op margin range%

9–28

$1 testx

—

Incr. ROIC%

—

BiOptic Inc., a biotechnology instrumentation company, develops scientific products for research and clinical applications. It offers instruments, such as bio-fragment analyzers and PCR thermocyclers; consumables, including DNA, RNA, and protein cartridges, as well as quantification kits; premix and polymerase PCR reagents; and veterinary, human, and food related testing kits.

Revenue by segment

No breakdown available

Revenue by region

No breakdown available

Reinvestment returns

No breakdown available